News | May 25, 2021
Bal Pharma launches BALflu, Favipiravir formulation in India
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
The product patent has been already filed under fast track approval
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Aarti Drugs has reported total income of Rs.2159.30 crores during the 12 months period ended March 31, 2021
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day
Subscribe To Our Newsletter & Stay Updated
